Capabilities by Industry: Healthcare
Greenhill has considerable transaction experience and a global network of corporate relationships in the Healthcare sector. Our Managing Directors and professionals in North America, the United Kingdom, Continental Europe and Australia have executed many of the most significant and complex transactions for some of the leading companies in the industry.
In addition to traditional M&A transactions, our team has extensive experience advising on complex partnering and licensing transactions.
Our experience in the Healthcare industry encompasses the following sub-sectors: healthcare services; life science tools; medical devices and services; branded, specialty and generic pharmaceuticals; and biotechnology.
Below we highlight a few of the transactions on which we have advised in this area:
Recent Transactions
Sort By
340B Link
Advising Omnicell, a leading provider of medication management solutions and adherence tools for health systems and pharmacies, on the acquisition of the 340B Link business from Pharmaceutical Strategies Group (PSG)
Cello Health plc
Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States
Equity stake in Bupa Arabia
Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, the largest health insurance provider in the Kingdom of Saudi Arabia
Global collaboration agreement with Genmab A/S
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
Cerner RevWorks
Advised Cerner Corporation, a leader in healthcare information technology, on its sale of its RevWorks revenue cycle management services business to R1 RCM, a leading provider of technology-enabled RCM services